0001104659-23-063202.txt : 20230522 0001104659-23-063202.hdr.sgml : 20230522 20230522165313 ACCESSION NUMBER: 0001104659-23-063202 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230522 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230522 DATE AS OF CHANGE: 20230522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 23945282 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 tm2316465d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 22, 2023

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-37359

26-3632015

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer
Identification No.)

45 Sidney Street

Cambridge, Massachusetts

02139

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 374-7580

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	BPMC	Nasdaq Global Select Market

Item 8.01

Other Events.

On May 22, 2023, Blueprint Medicines Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved the Company’s supplemental new drug application for AYVAKIT™ (avapritinib) for the treatment of adults with indolent systemic mastocytosis. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued by Blueprint Medicines Corporation on May 22, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BLUEPRINT MEDICINES CORPORATION

Date: May 22, 2023	By:	/s/ Kathryn Haviland
		Kathryn Haviland
		Chief Executive Officer

EX-99.1 2 tm2316465d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

FDA Approves AYVAKIT^®(avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

-- For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief --

-- Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and measures of mast cell burden, with a safety profile that compared favorably to placebo --

-- Blueprint Medicines to host investor conference call and webcast today at 4:30 p.m. ET --

CAMBRIDGE, Mass., May 22, 2023 -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT^® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM). All U.S. patients with ISM now have access to the first and only approved medicine designed to treat their disease.

Systemic mastocytosis (SM) is a rare hematologic disorder that can lead to a range of debilitating symptoms across multiple organ systems and a significant impact on patients’ quality of life. ISM represents the vast majority of SM cases, and AYVAKIT is now available for adults with ISM at the recommended dose of 25 mg once daily. AYVAKIT was designed to potently and selectively inhibit KIT D816V, the primary underlying driver of the disease. AYVAKIT has been FDA approved for the treatment of advanced SM since June 2021.

“Today’s approval of AYVAKIT reflects more than a decade of collaboration and leadership in the field of systemic mastocytosis, during which our team at Blueprint Medicines has worked closely with clinicians, patients and their families, and patient advocacy groups to advance innovative science and develop a transformational treatment for people living with the disease,” said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. “AYVAKIT is the first and only medicine approved by the FDA to treat indolent systemic mastocytosis, marking a shift in the treatment paradigm from supportive care to disease modifying therapy. In addition, AYVAKIT is the only treatment approved across the spectrum of indolent and advanced systemic mastocytosis. With a broad indication for indolent systemic mastocytosis and a strong label, we are now engaging healthcare providers to redefine what it means for their patients to be well-controlled as well as activating the patient community to seek out optimal care and treatment.”

“After decades of caring for people with indolent systemic mastocytosis, I have seen firsthand its profound impact on patients’ underlying mast cell burden, symptoms, physical and mental health, and ability to work and participate in daily activities,” said Cem Akin, M.D., Ph.D., Professor of Medicine at the University of Michigan,¹ and an investigator on the PIONEER trial.¹ “Despite the use of multiple supportive care treatments, a considerable number of patients with indolent systemic mastocytosis continue to experience a substantial disease burden. AYVAKIT advances the treatment of indolent systemic mastocytosis by targeting KIT D816V, the primary underlying cause of the disease, and establishes a new standard of care for a broad population of patients with this disorder. AYVAKIT delivered statistically significant and consistent clinical improvements in the PIONEER trial, and based on these practice-changing data, I feel a tremendous sense of hope for the future for all those affected by the disease.”

The approval of AYVAKIT in ISM is based on data from the double-blind, placebo-controlled PIONEER trial – the largest study ever conducted for this disease – in which patients received AYVAKIT 25 mg once daily plus best supportive care (AYVAKIT) or placebo plus best supportive care (placebo). AYVAKIT demonstrated significant improvements versus placebo in the primary and all key secondary endpoints, including overall symptoms and measures of mast cell burden.

AYVAKIT was well-tolerated with a favorable safety profile compared to placebo, and most adverse reactions were mild to moderate in severity. The most common adverse reactions for AYVAKIT (≥10 percent) were eye edema, dizziness, peripheral edema and flushing. Serious adverse reactions and discontinuations due to adverse reactions occurred in less than 1 percent of patients.

Detailed results from the PIONEER trial, including open-label extension study data showing the clinical benefits of AYVAKIT through 48 weeks of treatment, were presented in February 2023 at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

“People with indolent systemic mastocytosis are significantly impacted by their disease symptoms, and many individuals self-isolate at home to protect against unpredictable external triggers. Ultimately, the disease can disrupt an individual’s quality of life, career and ability to interact with family and friends, and those affected often face frequent healthcare visits and significant polypharmacy burden,” said Judith Kain Emmel, Board Chair of The Mast Cell Disease Society. “Since we began nearly 30 years ago, our goals as an organization have been to educate, advocate and collaborate for the advancement of knowledge and research in mast cell disorders like systemic mastocytosis. Today’s approval is a historic moment for the SM community and offers new hope for patients and their families. We are honored to have contributed to this milestone by facilitating SM community insights on the design of the PIONEER trial and supporting the development of the validated symptom assessment tool used in the study.”

Blueprint Medicines is committed to patient access and affordability for its approved medicines through YourBlueprint^®, which is designed to provide dedicated, personalized assistance for eligible patients. Commercially insured patients who qualify for the company’s co-pay assistance program may pay as little as $0 in out-of-pocket costs for AYVAKIT. YourBlueprint offers additional programs intended to facilitate timely access to therapy, including a patient assistance program for eligible patients who have inadequate insurance coverage. For more information, visit YourBlueprint.com or call 1-888-BLUPRNT (1-888-258-7768), Monday to Friday, 8:00 a.m. to 8:00 p.m. ET. Healthcare providers who prescribe AYVAKIT can fill out an enrollment form at YourBlueprint.com/HCP to help patients access Blueprint Medicines’ support programs.

Investor Conference Call Information

Blueprint Medicines will host a live conference call and webcast today at 4:30 p.m. ET to discuss the FDA approval of AYVAKIT in ISM. The conference call may be accessed by dialing 833-470-1428 (domestic) or 404-975-4839 (international), and referring to conference ID 832860. A webcast of the call will also be available under “Events and Presentations” in the Investors & Media section of the Blueprint Medicines website at https://ir.blueprintmedicines.com/. The archived webcast will be available on the Blueprint Medicines website approximately two hours after the conference call and will be available for 30 days following the call.

About AYVAKIT (avapritinib)

AYVAKIT (avapritinib) is a precision therapy approved by the FDA for the treatment of three indications: adults with ISM, adults with advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. For more information, visit AYVAKIT.com. This medicine is approved in Europe (AYVAKYT^®) for the treatment of adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. Please click here to see the full U.S. Prescribing Information for AYVAKIT, and click here to see the European Summary of Product Characteristics for AYVAKYT. AYVAKIT/AYVAKYT is not approved for the treatment of any other indication in the U.S. or Europe.

To learn about ongoing or planned clinical trials, contact Blueprint Medicines at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768). Additional information is available at blueprintclinicaltrials.com or clinicaltrials.gov.

About Systemic Mastocytosis

Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms across multiple organ systems. The vast majority of those affected have indolent systemic mastocytosis (ISM). A broad range of symptoms, including anaphylaxis, maculopapular rash, pruritis, diarrhea, brain fog, fatigue and bone pain, frequently persist in patients with ISM despite treatment with multiple symptom-directed therapies. This burden of disease can lead to a profound, negative impact on quality of life. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, and isolate themselves to protect against unpredictable triggers. Historically, there had been no approved therapies for the treatment of ISM.

A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including ASM, SM-AHN and MCL. In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor survival.

Important Safety Information

Intracranial Hemorrhage—Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In Advanced SM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 10⁹/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH.

Permanently discontinue AYVAKIT if ICH of any grade occurs. In Advanced SM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in Advanced SM patients with platelet counts <50 x 10⁹/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 10⁹/L by treatment interruption or dose reduction.

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 Advanced SM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose.

Adverse Reactions—The most common adverse reactions (≥20%) in patients with Advanced SM were edema, diarrhea, nausea, and fatigue/asthenia.

The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with Advanced SM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Please click here to see the full Prescribing Information for AYVAKIT.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines’ views with respect to the FDA approval of AYVAKIT/AYVAKYT and the implications of such approval for patients, caregivers and healthcare professionals; expectations regarding patients’ ability to rapidly access treatment with AYVAKIT/AYVAKYT; Blueprint Medicines’ plans and ability to provide robust support services for patients prescribed AYVAKIT/AYVAKYT through YourBlueprint; the potential benefits of Blueprint Medicines’ current and future approved drugs or drug candidates in treating patients, including expectations regarding the potential of AYVAKIT/AYVAKYT to address additional tumor types and treatment settings; and Blueprint Medicines’ strategy, goals and anticipated milestones, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to our ability and plans in continuing to expand Blueprint Medicines’ commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines’ ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of our current or future drug candidates; Blueprint Medicines advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines’ drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patent and other intellectual property protection for its products or any drug candidates it is developing; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for its products or any of its current and future drug candidates; Blueprint Medicines’ ability to successfully expand its research platform and the costs thereof; and the success of Blueprint Medicines’ current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 16, 2023, and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Reference

¹ Title provided for identification purposes only. The views and opinions expressed are those of the individual only and do not necessarily reflect the positions of the University of Michigan. Dr. Akin has a paid consulting/advisory relationship with Blueprint Medicines Corporation.

Trademarks

Blueprint Medicines, AYVAKIT, AYVAKYT, YourBlueprint and associated logos are trademarks of Blueprint Medicines Corporation.

Media Contact

Courtney Carroll

+1 (781) 264-7302

media@blueprintmedicines.com

Investor Relations Contact

Jenna Cohen

+1 (857) 209-3147

ir@blueprintmedicines.com

EX-101.SCH 3 bpmc-20230522.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bpmc-20230522_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bpmc-20230522_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	May 22, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 22, 2023
Entity File Number	001-37359
Entity Registrant Name	Blueprint Medicines Corporation
Entity Central Index Key	0001597264
Entity Tax Identification Number	26-3632015
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	45 Sidney Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02139
City Area Code	617
Local Phone Number	374-7580
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	BPMC
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2316465d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001597264 2023-05-22 2023-05-22 iso4217:USD shares iso4217:USD shares 0001597264 false 8-K 2023-05-22 Blueprint Medicines Corporation DE 001-37359 26-3632015 45 Sidney Street Cambridge MA 02139 617 374-7580 false false false false false Common stock, par value $0.001 per share BPMC NASDAQ EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://blueprintmedicines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2316465d1_8k.htm bpmc-20230522.xsd bpmc-20230522_lab.xml bpmc-20230522_pre.xml tm2316465d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2316465d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2316465d1_8k.htm" ] }, "labelLink": { "local": [ "bpmc-20230522_lab.xml" ] }, "presentationLink": { "local": [ "bpmc-20230522_pre.xml" ] }, "schema": { "local": [ "bpmc-20230522.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BPMC", "nsuri": "http://blueprintmedicines.com/20230522", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2316465d1_8k.htm", "contextRef": "From2023-05-22to2023-05-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://blueprintmedicines.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2316465d1_8k.htm", "contextRef": "From2023-05-22to2023-05-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-063202-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-063202-xbrl.zip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end